School of Medicine
Showing 2,081-2,100 of 2,306 Results
-
Randall Vagelos, MD
Professor of Medicine (Cardiovascular)
Current Research and Scholarly InterestsI. Congestive Heart Failure New Medical Therapies Prognostic Evaluation Selection for Cardiac Transplantation II. Screening for Myocardial Necrosis New ECG Monitoring Devices New Serum Markers III. Screening for CAD Patients Who Have Received Radiation Rx Diabetics Being Considered for Renal Transplantation
IV. Advanced coronary and valvular disease, evaluationg candidacy for high risk interventions. -
Sharif Vakili, MD, MBA, MS
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioSharif Vakili, MD, MBA, MS, (pronouns: he/him), is an internal medicine physician and educator. He practices at Stanford Los Altos Primary Care.
Dr. Vakili has a background in chronic disease management and health systems delivery, believing strongly in a teamwork approach to patient care that empowers patients to navigate the health system as part of their clinical care.
He is active in the research and business communities. His research has been in peer-reviewed journals including JAMA Network Open, the Annals of Emergency Medicine, Quality Management in Healthcare, and Journal of Clinical Rheumatology.
Dr. Vakili is also the inventor of Remote Patient Intervention (RPI), a model of clinician-supervised AI care delivery first performed at Stanford during a clinical study published in JAMA Network Open. -
Hannah Valantine
Professor of Medicine (Cardiovascular)
On Leave from 09/01/2024 To 08/31/2025Current Research and Scholarly InterestsMy lab is focused on understanding the mechanism mediating acute and chronic allograft failure, in particular on the role of microvascular injury in acute allograft failure and the mechanisms of mediating transplant coronary artery disease. 1. Role of microvascular injury in acute allograft failure.
-
Laura van Dam
Postdoctoral Scholar, Immunology and Rheumatology
BioI am both trained as a biomedical researcher and medical doctor in internal medicine and strive to close the gap between the clinic and fundamental sciences with translational research. My focus is to study the mechanisms of autoimmune diseases and to translate research insights into therapeutics targeting autoimmunity. I have received my PhD in 2022 in Leiden for studying neutrophil extracellular traps and autoreactive B cells in renal autoimmune diseases. My postdoctoral research project in the Robinson lab focuses on investigating the underlying molecular mechanisms of the pathogenesis of ANCA-associated vasculitis. I particularly aim to identify potential microbial triggers and molecular mimicry in ANCA-associated vasculitis, by characterizing the nasal microbiome and sequencing T cells and B cells of ANCA-associated vasculitis patients.
-
Laurens van de Wiel
Postdoctoral Scholar, Cardiovascular Medicine
BioLaurens van de Wiel is Dutch scientist from Berghem, The Netherlands. Laurens spent his undergrad in Software Development (BSc, Avans Hogeschool ‘s-Hertogenbosch) and Computing Science (MSc, Radboud University Nijmegen). Laurens continued his career at a start-up, where he created large-scale, real-time analytical software. Laurens continued on his academic trajectory at the Radboudumc in Nijmegen, where he started his PhD in bioinformatics.
During his PhD, Laurens integrated genetic data with protein 3D structures and protein domains. He utilized the skills he obtained before setting out on his academic trajectory; building large-scale, robust, reliable software. Exemplified by the MetaDome Web server (https://stuart.radboudumc.nl/metadome/). During his PhD, he developed novel methodologies for the interpretation of genetic variants of unknown clinical significance and, by integrating structural and evolutionary biology with genomics, Laurens identified 36 novel disease-gene associations for developmental disorders. These discoveries enabled diagnosis for over 500 families worldwide.
Laurens’ areas of expertise are (bioinformatic) software development, data integration of genetic variation with other omics, and his research aims are:
1.) Lessons long-learned in computer science aid computational biology
2.) Multi-omic data integration allows the impact measurement of genetic variation
3.) Diagnosing undiagnosed disorders will uncover novel insights into biology.
4.) International and multidisciplinary collaborations are key in diagnosing rare disorders.
At Stanford University, under guidance of Dr. Matthew Wheeler, he is conducting his postdoctoral studies in line with his research aims. -
Anubodh Sunny Varshney
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Anubodh Sunny Varshney is a Clinical Assistant Professor and Associate Director of the fellowship program in the section of Advanced Heart Failure, Transplant Cardiology, and Mechanical Circulatory Support at Stanford. In addition to caring for patients with advanced heart disease, he is also an Investigator in the Cardiovascular Outcomes, Policy, & Implementation Research Group (https://www.copirgroup.com/) where he works to identify patient groups that have ongoing unmet medical needs, define benchmark outcomes that next generation therapies should improve upon, and understand factors that influence adoption of novel drug and device therapies.
Dr. Varshney earned a BS in biomedical engineering from Washington University in St. Louis and an MD from the University of Texas Southwestern Medical School. He completed residency in Internal Medicine and fellowship in Cardiovascular Medicine at Brigham & Women’s Hospital/Harvard Medical School and fellowship in Advanced Heart Failure, Transplant Cardiology, and Mechanical Circulatory Support at Stanford University.
Dr. Varshney also has experience advising multiple medical device, drug, and digital health start-ups and currently serves as a Venture Advisor at Broadview Ventures, a philanthropically-funded, mission-driven investment organization that invests in early-stage companies developing technologies that have the potential to improve outcomes for patients with cardiovascular disease or stroke.
